Potential Molecular Cross Talk Among CCR5 Pathway Predicts Regorafenib Responsiveness in Metastatic Colorectal Cancer Patients.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Genetic variants in the CCL5/CCR5 pathway have been shown to predict regorafenib efficacy in patients with metastatic colorectal cancer (mCRC). This study investigated the biological role of CCL4 and CCL3 gene polymorphisms in patients with refractory mCRC treated using regorafenib.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Cancer Genomics Proteomics

Title: Cancer genomics & proteomics

Publisher: Anticancer Research USA Inc.

ISSN (Electronic): 1790-6245

ISSN (Print): 1109-6535

Publication date (Electronic): 2021

Volume: 18

Issue: 3

Affiliations

[1 ] Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, U.S.A.; m.suenaga1972@gmail.com.

[2 ] Gastroenterology Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

[3 ] Department of Specialized Surgeries, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.

[4 ] Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, U.S.A.

[5 ] Division of Molecular Biotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.

[6 ] Department of Preventive Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, U.S.A.

Article

Publisher Item ID: 18/3/317

DOI: 10.21873/cgp.20262

PMC ID: 8126324

PubMed ID: 33893084

SO-VID: 707ca202-f5cc-4341-9fe6-ba8c49a7a2cb

History

Keywords: metastatic colorectal cancer,regorafenib,CCL3,CCL4,CCL5,CCR5,SNPs

Data availability:

Keywords: metastatic colorectal cancer, regorafenib, CCL3, CCL4, CCL5, CCR5, SNPs

Potential Molecular Cross Talk Among CCR5 Pathway Predicts Regorafenib Responsiveness in Metastatic Colorectal Cancer Patients.

Read this article at

Abstract

Related collections

Bacterial extracellular vesicles

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 407

Cited by 2